MBX MBX Biosciences, Inc.
Company Analysis
Latest News
🔴 MBX Biosciences is trading 4.08% down in pre-market with no clear company-specific catalyst
MBX Biosciences is trading at $47.00, down 4.08% in pre-market, with no clear company-specific announcement explaining the decline. - On October 13, MBX...
🔴 MBX Biosciences is trading 4.3% down today amid biotech-sector weakness
MBX Biosciences is trading 4.33% lower at $49.77, with no clear company-specific news explaining the October 13 decline. - The company announced upcoming...
🔴 MBX Biosciences is trading 4.66% down today amid biotech-sector and broader market pressure
MBX Biosciences is trading at $52.00, down 4.66%, amid biotech-sector and broader market pressure. - During the October 8 session, no new company-specific...
🔴 MBX Biosciences is trading 4.55% down today amid rising Treasury yields
MBX Biosciences is trading 4.55% lower at $54.33, amid pressure on biotech stocks as Treasury yields rose above 5.3%. - Investors were awaiting Federal Reserve...
🔴 MBX Biosciences is trading 4.22% down as biotech stocks weaken
MBX Biosciences is trading 4.22% lower at $56.07, with biotech-sector weakness the likeliest explanation. - On October 6, 2026, XBI was down 2.50%, while...
MBX Biosciences Gets $150 Target on Obesity Drug Potential
Guggenheim maintained its Buy rating on MBX Biosciences. The firm raised its price target from $88 to $150. MBX shares were trading at $56.55. The new target...
🟢 MBX Biosciences is trading 5% up with no clear company-specific catalyst identified
MBX Biosciences is trading at $59.28, up 4.83%, with no clear company-specific catalyst identified. - No company-specific announcement explaining the October...
🟢 MBX Biosciences is trading 4.18% up with no clear catalyst identified
On September 28, 2026, MBX Biosciences is trading 4.18% higher at $55.87, with no confirmed catalyst identified. - The company’s investor-relations release...
🔴 MBX Biosciences is trading 4.08% down today as catalyst remains unconfirmed
MBX Biosciences is trading 4.08% lower at $53.13; no specific catalyst for the September 25, 2026 decline has been identified. - No new company-specific...
🔴 MBX Biosciences is trading 4.37% down today amid a 19-year-high 10-year Treasury yield
MBX Biosciences is trading 4.37% lower at $55.36 as broader risk-off pressure weighs on biotechnology and growth stocks. - The Nasdaq is down 0.87%, while...
🔴 MBX Biosciences is trading 4.3% down today
MBX Biosciences is trading 4.3% lower at $59.32, with no confirmed company-specific announcement identified for September 23, 2026. - Its investor-relations...
🟢 MBX Biosciences is trading 4.3% up in pre-market; reason remains unconfirmed
MBX Biosciences is trading at $63.53 (+4.25%) in pre-market on September 22, 2026; the reason remains unconfirmed. - Recent coverage centers on the September...
🔴 MBX Biosciences is trading 4% down today with no clear company-specific catalyst
MBX Biosciences is trading 4.03% down at $60.38 after no clear company-specific negative catalyst emerged on September 21, 2026. - Recent coverage highlights...
🟢 MBX Biosciences rises 5.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 MBX Biosciences is trading 4.3% down today amid geopolitical risk and hawkish Fed expectations
MBX Biosciences is trading at $60.30 (-4.29%) as broader markets decline amid rising geopolitical risk, oil prices, and hawkish Federal Reserve...
🔴 MBX Biosciences falls 4.4% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
MBX Biosciences Doses First Patient in Pivotal Phase 3 Hypoparathyroidism Trial
MBX Biosciences announced it has dosed the first patient in its pivotal Phase 3 clinical trial, named "oPTimize," for its drug candidate canvuparatide. The...
🟢 MBX Biosciences is trading 4.5% up today
MBX Biosciences is trading 4.5% up at $69.37, while the direct catalyst remains unclear. - No new company-specific announcement dated August 25, 2026 was...
MBX Biosciences Rated Overweight at JPMorgan, Citing $88 Obesity Pipeline Target
JPMorgan resumed coverage of MBX Biosciences with an Overweight rating. The investment bank established a price target of $88 per share. Analyst Jessica Fye...
🔴 MBX Biosciences falls 4.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...